Sun Pharmaceutical Industries SUNPHARMA
India's largest drugmaker: No. 1 in the Indian branded market, a growing global innovative-medicines (specialty) business and US generics via Sun and Taro
Mapped in 2 themes: Nifty 50 and Pharmaceuticals.
Where Sun Pharmaceutical Industries sits in the supply chain
Sun Pharmaceutical Industries appears in 3 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › India branded formulations
OperatorOther companies in this layer
Pharmaceuticals › Specialty & innovation (R&D)
OwnerOther companies in this layer
Pharmaceuticals › Generics (US & export)
Direct supplierOther companies in this layer
Index membership
Sun Pharmaceutical Industries is in the Nifty 50 (NSE industry: Healthcare).
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 48,497 | 52,578 | 58,462 |
| Net profit | 9,610 | 10,965 | 11,509 |
Latest-year revenue ₹58,462 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Global innovative medicines (Ilumya, Cequa, Winlevi, Leqselvi, Unloxcyt) were ~22% of sales in Q1 FY27 and growing double digits - the largest specialty franchise of any Indian company
- No. 1 by share in the Indian pharmaceutical market with a chronic-heavy portfolio
- Agreed (Apr 2026) to buy Organon for US$11.75bn EV - adds women's health, biosimilars and ~140-country reach; combined revenue ~US$12.4bn per company
Risks
- Organon deal (expected to close early 2027) takes net debt/EBITDA to ~2.3x and brings integration risk
- US generics fell ~10% YoY in Q1 FY27 on price erosion; Halol remains OAI (Jun 2025) and under import alert
- Specialty launch spending (Leqselvi, Unloxcyt) is now a structural cost
Common questions
What does Sun Pharmaceutical Industries do?
India's largest drugmaker: No. 1 in the Indian branded market, a growing global innovative-medicines (specialty) business and US generics via Sun and Taro.
Where does Sun Pharmaceutical Industries sit in the supply chain?
Sun Pharmaceutical Industries (NSE: SUNPHARMA) is mapped in 3 supply-chain layers: India branded formulations (Pharmaceuticals), Specialty & innovation (R&D) (Pharmaceuticals) and Generics (US & export) (Pharmaceuticals).
Who are Sun Pharmaceutical Industries' peers?
In the India branded formulations layer of Pharmaceuticals: Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Abbott India, Eris Lifesciences, Cipla and 4 more.
What is Sun Pharmaceutical Industries' market cap and valuation?
As of 30 Oct 2026: market cap ₹4.26L Cr, P/E 34.6x, ROCE 20.5%, ROE 16.0%, dividend yield 0.90%.